Phaseline

Companies › Arsenal Biosciences

Arsenal Biosciences: clinical trials, targets and expected readouts

3 active drug programs in 3 registered trials: 3 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
AB-2100
Integrated Circuit T cell therapy; autologous T cells engineered with synthetic immunologi
–Phase 1Advanced/Metastatic Clear Cell Renal Cell CarcinomaDec 2026
AB-3028
Programmable circuit autologous T cell therapy
–Phase 1Metastatic Castration Resistant Prostate Cancer (mCRPC)May 2029
AB-1015
Integrated Circuit T (ICT) cells; autologous T cell therapy
–Phase 1Carcinoma, Ovarian Epithelial–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05617755AB-1015Phase 1Carcinoma, Ovarian EpithelialOncologySep 2024
NCT06245915AB-2100Phase 1Advanced/Metastatic Clear Cell Renal Cell CarcinomaOncologyDec 2026
NCT07285694AB-3028Phase 1Metastatic Castration Resistant Prostate Cancer (mCRPC)OncologyMay 2029

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.